普雷马林单用及普雷马林+倍氯米松联合治疗对造血干细胞移植后阴道受累GVHD的影响

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-05-01 DOI:10.1016/j.transproceed.2025.03.021

Mansooreh Yaraghi , Mohammadamin Noorafrooz , Maryam Motezarre , Seyed Asadollah Mousavi

{"title":"普雷马林单用及普雷马林+倍氯米松联合治疗对造血干细胞移植后阴道受累GVHD的影响","authors":"Mansooreh Yaraghi , Mohammadamin Noorafrooz , Maryam Motezarre , Seyed Asadollah Mousavi","doi":"10.1016/j.transproceed.2025.03.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Vaginal Graft-versus-Host Disease (GVHD) is a common complication after hematopoietic stem cell transplantation, leading to inflammation and fibrosis of the vaginal tissue. This study was conducted to compare the effectiveness of Premarin alone versus Premarin + Beclomethasone in patients with vaginal GVHD.</div></div><div><h3>Methods</h3><div>40 patients with vaginal GVHD after hematopoietic stem cell transplantation at (XXX) during the years 2018 to 2020 were randomly assigned to 2 groups: the Premarin recipient group (22 individuals) or the Premarin + Beclomethasone group (18 individuals). Symptoms, including vaginal dryness, dyspareunia, discharge, vaginal tightness, etc., were assessed before and after 6 weeks of treatment.</div></div><div><h3>Results</h3><div>After treatment, most symptoms improved in both groups. The Premarin group showed improvement in 21 out of 25 symptoms (84%), while the combination group demonstrated improvement in 22 out of 25 symptoms (88%), with no significant difference between the groups (<em>P ></em> .05). The only symptom with significantly greater improvement in the combination group was vaginal tightness, which occurred in 3 out of 18 patients (17%) compared to 1 out of 22 patients (4.5%) in the Premarin group (<em>P</em> = .03).</div></div><div><h3>Conclusions</h3><div>The combination of Premarin and Clobetasol is more effective than Premarin alone, particularly in cases of vaginal tightness. Other symptoms may be associated with atrophic manifestations.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 5","pages":"Pages 885-890"},"PeriodicalIF":0.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Treatment With Premarin Alone and the Combination of Premarin + Beclomethasone in Vaginal Involvement of GVHD After Hematopoietic Stem Cell Transplantation\",\"authors\":\"Mansooreh Yaraghi , Mohammadamin Noorafrooz , Maryam Motezarre , Seyed Asadollah Mousavi\",\"doi\":\"10.1016/j.transproceed.2025.03.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Vaginal Graft-versus-Host Disease (GVHD) is a common complication after hematopoietic stem cell transplantation, leading to inflammation and fibrosis of the vaginal tissue. This study was conducted to compare the effectiveness of Premarin alone versus Premarin + Beclomethasone in patients with vaginal GVHD.</div></div><div><h3>Methods</h3><div>40 patients with vaginal GVHD after hematopoietic stem cell transplantation at (XXX) during the years 2018 to 2020 were randomly assigned to 2 groups: the Premarin recipient group (22 individuals) or the Premarin + Beclomethasone group (18 individuals). Symptoms, including vaginal dryness, dyspareunia, discharge, vaginal tightness, etc., were assessed before and after 6 weeks of treatment.</div></div><div><h3>Results</h3><div>After treatment, most symptoms improved in both groups. The Premarin group showed improvement in 21 out of 25 symptoms (84%), while the combination group demonstrated improvement in 22 out of 25 symptoms (88%), with no significant difference between the groups (<em>P ></em> .05). The only symptom with significantly greater improvement in the combination group was vaginal tightness, which occurred in 3 out of 18 patients (17%) compared to 1 out of 22 patients (4.5%) in the Premarin group (<em>P</em> = .03).</div></div><div><h3>Conclusions</h3><div>The combination of Premarin and Clobetasol is more effective than Premarin alone, particularly in cases of vaginal tightness. Other symptoms may be associated with atrophic manifestations.</div></div>\",\"PeriodicalId\":23246,\"journal\":{\"name\":\"Transplantation proceedings\",\"volume\":\"57 5\",\"pages\":\"Pages 885-890\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplantation proceedings\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0041134525002118\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134525002118","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：阴道移植物抗宿主病（GVHD）是造血干细胞移植后常见的并发症，可导致阴道组织炎症和纤维化。本研究旨在比较单用普雷马林与普雷马林+倍氯米松治疗阴道GVHD患者的疗效。方法：选取2018 ~ 2020年（XXX）点造血干细胞移植后阴道GVHD患者40例，随机分为2组：普雷马林受体组（22例）和普雷马林+倍氯米松组（18例）。在治疗前和治疗后6周评估症状，包括阴道干燥、性交困难、分泌物、阴道紧绷等。结果：治疗后两组患者症状均有明显改善。普雷马林组在25项症状中有21项（84%）得到改善，而联合用药组在25项症状中有22项（88%）得到改善，两组间无显著差异（P < 0.05）。联合组唯一明显改善的症状是阴道紧绷，18例患者中有3例（17%）出现阴道紧绷，而普雷马汀组22例患者中有1例（4.5%）出现阴道紧绷（P = .03）。结论：普雷马林联合氯倍他索比单用普雷马林更有效，特别是在阴道紧绷的情况下。其他症状可能与萎缩表现有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effects of Treatment With Premarin Alone and the Combination of Premarin + Beclomethasone in Vaginal Involvement of GVHD After Hematopoietic Stem Cell Transplantation

Background

Vaginal Graft-versus-Host Disease (GVHD) is a common complication after hematopoietic stem cell transplantation, leading to inflammation and fibrosis of the vaginal tissue. This study was conducted to compare the effectiveness of Premarin alone versus Premarin + Beclomethasone in patients with vaginal GVHD.

Methods

40 patients with vaginal GVHD after hematopoietic stem cell transplantation at (XXX) during the years 2018 to 2020 were randomly assigned to 2 groups: the Premarin recipient group (22 individuals) or the Premarin + Beclomethasone group (18 individuals). Symptoms, including vaginal dryness, dyspareunia, discharge, vaginal tightness, etc., were assessed before and after 6 weeks of treatment.

Results

After treatment, most symptoms improved in both groups. The Premarin group showed improvement in 21 out of 25 symptoms (84%), while the combination group demonstrated improvement in 22 out of 25 symptoms (88%), with no significant difference between the groups (P > .05). The only symptom with significantly greater improvement in the combination group was vaginal tightness, which occurred in 3 out of 18 patients (17%) compared to 1 out of 22 patients (4.5%) in the Premarin group (P = .03).

Conclusions

The combination of Premarin and Clobetasol is more effective than Premarin alone, particularly in cases of vaginal tightness. Other symptoms may be associated with atrophic manifestations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.